HealthZanidatamab Regimen Shows 39.8% Estimated Three-Year SurvivalBy Naomi CalderOct 24, 2026, 1:20 AM UTC
BusinessBeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 11, 2017, 3:00 PM UTC
